THQ struggles with healthcare sector underperformance and trades at a premium. Read the full report on why THQ's high yield ...

DRI Healthcare Trust terminated management agreement with DRI Capital in exchange for $48M, plus accrued management and ...

Debt-to-equity ratios vary by company and industry, but in general, a ratio of 1.0 or less is considered rather safe. One of ...

Only a few days prior, Sanofi also stated that it would simplify its R&D structure, but noted only that an undisclosed number of staff would leave.

Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced that it has completed its previously announced transaction to internalize its investment management function.

The combo has already bagged priority review from the FDA. Although Keytruda/Inlyta had a higher rate of adverse events than Sutent (62.9% vs 58.1%) it had lower discontinuation rates (6.3% vs 10.1%).

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

Here the authors combine a deep generative model with structure-based drug design and prospectively validate functionally active, nanomolar, A 2A adenosine receptor ligands and solve their crystal ...